Revenue
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Medtronic plc (MDT)
Price$88.51Cached quote
Net income
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $36.36B | $33.54B | $32.36B | $31.23B | $31.69B | $30.12B | $28.91B | $30.56B | $29.95B | $29.71B | $28.83B | $20.26B | $17.00B | $16.59B |
| Gross profit | $23.64B | $21.91B | $21.15B | $20.51B | $21.54B | $19.63B | $19.49B | $21.40B | $20.90B | $20.42B | $19.69B | $13.95B | $12.67B | $12.46B |
| Gross margin | 65.02% | 65.32% | 65.34% | 65.67% | 67.98% | 65.19% | 67.41% | 70.04% | 69.77% | 68.73% | 68.29% | 68.86% | 74.52% | 75.13% |
| Research & development | $2.87B | $2.73B | $2.73B | $2.70B | $2.75B | $2.49B | $2.33B | $2.33B | $2.26B | $2.19B | $2.22B | $1.64B | $1.48B | $1.56B |
| Operating expenses | $17.18B | $15.95B | $16.00B | $15.02B | $15.79B | $15.15B | $14.70B | $15.13B | $14.26B | $15.04B | $14.33B | $10.19B | $8.86B | $8.06B |
| Operating income | $6.47B | $5.96B | $5.14B | $5.49B | $5.75B | $4.48B | $4.79B | $6.27B | $6.64B | $5.38B | $5.36B | $3.77B | $3.81B | $4.40B |
| Operating margin | 17.78% | 17.76% | 15.89% | 17.56% | 18.15% | 14.89% | 16.57% | 20.51% | 22.17% | 18.12% | 18.59% | 18.59% | 22.42% | 26.53% |
| EBITDA | $9.43B | $8.82B | $7.79B | $8.18B | $8.46B | $7.19B | $7.45B | $8.93B | $9.28B | $8.30B | $8.18B | $5.07B | $4.66B | $5.22B |
| EBITDA margin | 25.92% | 26.29% | 24.07% | 26.20% | 26.70% | 23.86% | 25.78% | 29.21% | 31.00% | 27.94% | 28.37% | 25.03% | 27.42% | 31.47% |
| Net income | $4.80B | $4.66B | $3.68B | $3.76B | $5.04B | $3.61B | $4.79B | $4.63B | $3.10B | $4.03B | $3.54B | $2.67B | $3.06B | $3.47B |
| Net profit margin | 13.20% | 13.90% | 11.36% | 12.03% | 15.90% | 11.97% | 16.56% | 15.16% | 10.36% | 13.56% | 12.27% | 13.20% | 18.02% | 20.90% |
| Basic EPSper basic share | $3.75 | $3.63 | $2.77 | $2.83 | $3.75 | $2.68 | $3.57 | $3.44 | $2.29 | $2.92 | $2.51 | $2.44 | $3.06 | $3.40 |
| Diluted EPSper diluted share | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.54 | $3.41 | $2.27 | $2.89 | $2.48 | $2.41 | $3.02 | $3.37 |
Owners
Reported shareholders
≈8.91%of listed shares
BlackRock, Inc.114.02M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
BlackRock, Inc. | ≈8.91%114.02M shares |
VANGUARD CAPITAL MANAGEMENT LLC | ≈6.55%83.82M shares |
STATE STREET CORP | ≈4.95%63.4M shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | ≈2.66%34.06M shares |
GEODE CAPITAL MANAGEMENT, LLC | ≈2.36%30.19M shares |
JPMORGAN CHASE & CO | ≈2.17%27.78M shares |
First Eagle Investment Management, LLC | ≈2.15%27.57M shares |
BANK OF AMERICA CORP /DE/ | ≈1.67%21.32M shares |
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ≈1.55%19.87M shares |
MORGAN STANLEY | ≈1.52%19.44M shares |
DEUTSCHE BANK AG\ | ≈1.44%18.45M shares |
Invesco Ltd. | ≈1.40%17.89M shares |
FRANKLIN RESOURCES INC | ≈1.37%17.55M shares |
NORGES BANK | ≈1.29%16.55M shares |
ROYAL BANK OF CANADA | ≈1.25%16.03M shares |
Bank of New York Mellon Corp | ≈1.15%14.69M shares |
Capital Research Global Investors | ≈1.04%13.26M shares |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ≈1.01%12.89M shares |
NORTHERN TRUST CORP | ≈0.91%11.63M shares |
AMERIPRISE FINANCIAL INC | ≈0.90%11.57M shares |
Percentages use 1.28B shares of this listed class outstanding on Jun 12, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 8, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 228 | $80.45 | $18.3K | 37.2K |
| Jun 8, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 4.0K | $80.44 | $318.6K | 37.5K |
| Feb 19, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 385 | $97.82 | $37.7K | 32.8K |
| Feb 19, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 668 | $97.83 | $65.4K | 33.2K |
| Feb 19, 2026Form 4 | KIIL HARRY SKIPEVP & President Cardiovascular | SellOrdinary Shares | 19.3K | $97.77 | $1.88M | 33.8K |
Community posts
Medtronic gains cardiac-software clearances across two ablation platforms
Medtronic ($MDT) obtained FDA clearance and a European CE mark for its latest Affera Prism-2 cardiac mapping software, alongside a CE mark for the PulseSelect ProxBox adapter and Proximity Indicator software. The Affera upgrade adds tools f ...
Medtronic’s GI Genius system shows gains in large clinical-practice study
Cosmo reported new results for GI Genius, the AI-assisted endoscopy system it develops and Medtronic ($MDT) commercializes. The cluster-randomized quality-improvement study covered more than 334,000 colonoscopies across 139 US Veterans Heal ...
Medtronic wins FDA clearance for LigaSure instrument on Hugo robot
Medtronic ($MDT) received FDA clearance for the LigaSure RAS Maryland jaw instrument for its Hugo robotic-assisted surgery system. The instrument brings the company’s vessel-sealing technology to the robotic platform and is designed to seal ...
Medtronic launches MiniMed share-exchange offer
Medtronic ($MDT) launched an exchange offer to split off at least 80.1% of MiniMed ($MMED), its former diabetes business. Investors can voluntarily exchange Medtronic shares for MiniMed stock at a 7% discount, subject to a cap of 4.5939 Min ...
Medtronic begins European clinical use of its Stealth AXiS surgical system
Medtronic ($MDT) announced the first European procedures using its Stealth AXiS surgical system, with more than 23 procedures performed across seven sites in Germany, the UK, Italy and Spain. The initial experience includes spinal surgery. ...
